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Abstract
Layer-by-layer (LbL) self-assembly is a versatile technique from which multicomponent and 
stimuli-responsive nanoscale drug carriers can be constructed. Despite the benefits of LbL 
assembly, the conventional synthetic approach for fabricating LbL nanoparticles requires 
numerous purification steps that limit scale, yield, efficiency, and potential for clinical translation. 
In this report, we describe a generalizable method for increasing throughput with LbL assembly by 
using highly scalable, closed-loop diafiltration to manage intermediate purification steps. This 
method facilitates highly controlled fabrication of diverse nanoscale LbL formulations smaller 
than 150 nm composed from solid-polymer, mesoporous silica, and liposomal vesicles. The 
technique allows for the deposition of a broad range of polyelectrolytes that included native 
polysaccharides, linear polypeptides, and synthetic polymers. We also explore the cytotoxicity, 
shelf life and long-term storage of LbL nanoparticles produced using this approach. We find that 
LbL coated systems can be reliably and rapidly produced: specifically, LbL-modified liposomes 
could be lyophilized, stored at room temperature, and reconstituted without compromising drug 
encapsulation or particle stability, thereby facilitating large scale applications. Overall, this report 
describes an accessible approach that significantly improves the throughput of nanoscale LbL 
drug-carriers that show low toxicity and are amenable to clinically relevant storage conditions.
Graphical Abstract
The highly scalable preparation of drug-loadable, layer-by-layer nanoparticles is described 
for a variety of formulations below 150 nm in size. This work demonstrates a method to 
generate layer-by-layer drug-carriers in a manner that is both facile and much higher throughput 
than traditional methods. Results also reveal the generated nanoparticles possess clinically relevant 
shelf lives as well as compatibility with long-term freeze-dried storage.
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1. Introduction
Multifunctional nanoscale therapies have the capacity to transform modern healthcare by 
providing greater control over the spatial and temporal release of drugs.[1] Formulations 
sized from 15 to 100 nm exhibit unique properties and functions that promote accumulation 
in target tissues while minimizing nonspecific clearance from the body.[2] These 
nanotherapies are by their own nature a complex composite of materials that can 
simultaneously protect, guide, and release biologically active compounds in a desirable 
manner. Complex materials, in turn, provide significant challenges from a translational point 
of view – particularly in terms of their eventual scalable fabrication. Effective nanoscale 
therapies must further exhibit adequate shelf lives under clinically relevant storage 
conditions in order to facilitate their eventual translation.
LbL assembly is a well-established technique for the solution-phase synthesis of hierarchical 
and multifunctional nanoscale therapeutics.[3] LbL nanoparticles can possess a range of 
desirable properties for drug and gene delivery due to the versatility granted by the 
technique. In its most frequently employed form, LbL assembly is driven by the electrostatic 
interaction between oppositely charged polyelectrolytes on a charged substrate. Possible 
substrates include colloids such as gold, polymer, silica, and liposomal nanoparticles, 
amongst others.[4] Along with the flexibility in the choice of a core substrate, any 
polyelectrolyte with a multivalent charge can be incorporated into an LbL construct, 
including native polysaccharides, nucleic acids, linear polypeptides, and synthetic 
polymers.[4a, 5] The LbL technique has been well characterized and studied by the materials 
community since the fundamental concept of alternating electrostatic assembly was first 
described by Iler in 1966.[6] In addition to electrostatics, it is well documented that LbL 
assembly can be driven by a multitude of intermolecular interactions that include hydrogen 
bonding, covalent bonding, and biologically specific interactions.[7] More recent research 
into LbL nanomaterials has yielded important developments for a variety of fields including 
chemical sensing, catalysis, energy storage, optics, and drug delivery.[4f, 8]
Several advances specifically highlight the promise of LbL nanoparticle systems for drug 
delivery, including the ability to generate novel hybrid organic-inorganic nanoparticles with 
tunable cell-particle interactions, and the generation of nanoparticle systems that can release 
combination drugs and small interfering RNA (siRNA) in a staged and synergistic fashion.[9] 
Importantly, the thickness of polyelectrolyte multilayers formed by LbL is on the order of 
nanometers, providing investigators a high degree of control over the final size of an LbL 
nanoparticle. As generally the polymer film is very thin, the size of an LbL formulation is 
largely determined by the core substrate, which has been reported to be as small as 10 nm in 
diameter.[10] Using the LbL platform, researchers have been able to preserve the size of a 
conventional nanoparticle formulation while providing improved stability and 
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environmentally sensitive functionalities that capitalize on cues from the tumor 
microenvironment to initiate cellular uptake.[5b, 11] Additional functionalities provided by 
the multilayer film allows for tuning of drug release and the incorporation of therapeutics 
into the polymer film.[4f, 9b, 12]
Despite their numerous advantages, both basic research and clinical translation of LbL 
nanoparticles have been impeded by scalability problems associated with their preparation. 
Traditional preparation of these materials relies on centrifugal purification to eliminate 
excess polyelectrolyte, but this approach is both time-intensive and prone to causing 
irreversible aggregation of LbL particles. Unfortunately, centrifugation becomes much more 
problematic when transitioning from micro- to nanoscale formulations, due to the need to 
significantly increase the spin speed and time needed to isolate smaller particles. Work to 
optimize centrifugal protocols rely on meticulous optimization of polymer molecular weight, 
charge ratios, centrifugal force, and spin times.[13] Efforts to try and resolve problems with 
scalability have generated creative techniques including vacuum-filtration, atomization, 
microfluidic, electrophoresis, and fluidized bed-mediated LbL assembly.[14] While these 
innovative approaches do offer advances in efficacy and yield during the preparation of 
colloidal LbL materials, they place limitations on the types and sizes of materials that can be 
used, reducing LbL versatility. Our group previously described another LbL preparation 
method, which relies on PRINT® technology. While this approach is robust, it does not 
allow for the layering of many nanoparticle cores that are of great interest for drug delivery 
and theranostics, such as quantum dots, liposomes, and responsive self-assembled polymeric 
colloids.[15]
To address the need for an accessible, robust, and scalable approach for preparing diverse 
LbL nanoparticles, we incorporated tangential flow filtration (TFF) into our synthetic 
workflow. TFF works by a process known as diafiltration, where permeable molecules are 
removed from a solution while passing through a hollow ultrafiltration membrane. 
Diafiltration for nanoparticle purification has been well characterized for colloidal 
solutions.[16] When a solution of LbL nanoparticles is pumped through the fiber membrane, 
the permeable polyelectrolytes rapidly exit through the pores in the membrane and are 
removed from the system. Meanwhile, the larger nanoparticles are retained and re-circulated 
through the system until the desired purity is reached. The sample volume can be held 
constant by the introduction of replacement buffer at the same rate that waste is removed 
from the system, allowing the purification to be continued for any desired amount of time. 
Collected waste (permeate) solution can also be recovered and re-concentrated in order to 
recycle reagents and reduce synthetic costs. Furthermore, these devices are easily scalable to 
prepare samples ranging anywhere from a single milliliter to more than a liter.
Lohse and colleagues previously described the use of a TFF-based reactor for the synthesis 
and functionalization of gold nanoparticles, including LbL modification with poly(acrylic 
acid) and polyallylamine.[17] This early application of TFF towards LbL modification faced 
issues of efficient purification, requiring washing nanoparticles with upwards of 20 volume 
equivalents before achieving sufficient purity to perform the next deposition step. Inefficient 
polyelectrolyte removal also appeared to cause off-target toxicity due to the carryover of free 
polycations. Here, we employ high surface-area, porous hollow-fiber filtration cassettes that 
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provide improved flux rates that allow TFF purification to occur more rapidly and 
completely. Indeed, very recently the work by Björnmalm and coworkers demonstrated the 
effective preparation of LbL particles with this new class of membrane, with more emphasis 
on the generation of micrometer- and submicrometer-sized particles and capsules.[18] Here, 
we specifically describe a generalizable method for using TFF to prepare LbL nanoparticles 
ranging from 40 to 150 nm, which are within the size range important for systemic drug 
delivery, tumor targeting, and tissue penetration. We document major improvements in 
efficiency and yield using this method relative to traditional protocols. Furthermore, we 
demonstrate the compatibility of this method with a broad range of biomedically relevant 
materials through the fabrication of LbL nanoparticles composed from a variety of substrates 
and biocompatible polyelectrolytes, and include several novel LbL formulations. To 
highlight the clinical relevance of these materials, we go on to demonstrate that LbL 
nanoparticles fabricated using this new technique are biocompatible, and can be stably 
stored in both refrigerated and lyophilized states.
2. Results and Discussion
2.1. Preparation Of Filter Membranes For LbL Assembly
In LbL assembly, the role of salts is well known to promote the generation of thicker films 
by shielding the Coulombic repulsion between adsorbed polyelectrolytes.[13, 19] While this 
phenomenon can provide a measure of control over film thickness, it also promotes particle 
flocculation by masking the repulsive forces between distinct particles. The inclusion of salt 
is particularly problematic in LbL formulations where the researcher must balance the 
electrostatic repulsion between polyelectrolytes that are also subject to intermolecular 
attractive forces like hydrogen bonding. Consideration for delicate materials aside, the 
purification of LbL particles requires the eventual removal of salt to halt the gradual re-
organization and decomposition of the LbL film.[19c] Normally, salt-removal is 
accomplished by using pure water during the sequential centrifugal washing steps, where 
salt-removal actually helps to better stabilize the particles by improving their electrostatic 
repulsion. Unfortunately, this poses a challenge for efficient purification using filtration, due 
to the slight negative charge associated with most polymeric filter membranes.[14a, 20] For 
LbL preparations, the sequential exposure of alternatively charged particle-polymer 
solutions leads to the build up of an LbL film onto the filter membrane itself, which reduces 
yields and fouls the membrane.[21]
To overcome this problem, we separate the purification of positively and negatively charged 
particles to their own filter membranes (Figure 1a). To discourage cationic nanoparticles 
from adhering to the negative membrane walls, dilute solutions of free polycation (10 mg 
mL−1) are re-circulated through the filter membrane for 10 minutes. This pre-treatment 
allows free polycation to bind to anionic sites on the membrane via electrostatic attraction, 
and reduces the membrane’s capacity for nonspecific adsorption of cationic species during 
subsequent purification. For the membrane that processes negatively charged particles, no 
modifications were made as its intrinsic negative charge suitably repels nonspecific 
adsorption. Separation of charge to specific membranes greatly improved yields with salt-
free conditions and allowed us to easily and quickly prepare diverse LbL constructs.
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2.2. LbL Nanoparticle Synthesis And Characterization
2.2.1. Purification Kinetics and Product Yields
We assessed purification kinetics using 500 kDa molecular weight cut off (MWCO) 
membranes and observed the rapid removal of excess 15 kDa poly(L-lysine) (PLL) and 10 
kDa dextran sulfate (DXS) from an LbL nanoparticle grown on a fluorescently labeled, 100 
nm, carboxy-modified latex (CML) substrate (Figure 1b). During purification, permeate 
waste was sequentially collected and then analyzed by either the bicinchoninic acid (BCA) 
assay or by gel permeation chromatography (GPC) to quantify the removal of 
polyelectrolyte. The results indicated that removal of polyelectrolytes of this size reaches a 
plateau within four minutes of purification while operating the TFF at a transmembrane 
pressure between 3–5 PSI. We applied a linear regression analysis to fit the data and 
calculate the time required to reach a desired purity. The results were similar to the 
qualitative interpretation of the data, indicating that 95% purity could be expected in 5.1 
minutes for PLL and 3.8 minutes for the smaller DXS.
To assess the yield from TFF-assisted LbL synthesis, we repeatedly fabricated ten-layer LbL 
particles composed of a fluorescently labeled, 100 nm CML core coated with 15 kDa PLL 
and 10 kDa DXS (100CML-[PLL/DXS]5). After each purification step, a sample was taken 
to quantify particle recovery. Data from three independent syntheses were combined to 
determine the typical yield possible using this technique (Figure 1c). The results indicated 
that a total yield of 68 ± 5% could be expected after ten layer depositions. Linear regression 
analysis of the data suggested that 96.9 ± 0.4% yield could be expected per layer deposition.
One of the major findings of this work was the rapid timescale of nanoparticle purification 
using TFF, which reduced purification time to 4–6 minutes per layer. Relative to the 30–60 
minutes typically required for a single centrifugal spin during traditional synthesis, TFF-
assisted LbL assembly is dramatically more efficient. Analysis of recovered permeates 
during the purification of either 15 kDa PLL or 10 kDa DXS revealed that free polymers 
were efficiently removed after washing with 5 volume equivalents of the eluent solution, a 
significant improvement upon the 20 equivalents required by previous TFF-based 
approaches for nanoparticles.[17]
Using our diafiltration-based system, rapid purification times are complimented by a 
reliable, high degree of product yield of 96.9 ± 0.4% per layer, leading to 68 ± 5% yield 
after ten layer depositions on 100 nm latex cores. This provides 83 ± 2% yield after four 
layer depositions, which is the number of layers in the formulations we have previously 
described for applications involving targeted drug delivery to tumors.[9b] These results are a 
marked improvement over previously published optimized centrifugal protocols that report a 
54.1% yield after the deposition of ten layers.[13] Improved yields will facilitate the 
exploration of LbL drug-carriers that incorporate useful but costly materials, such as siRNA, 
into the multilayer film. Similarly, recovery of the polyelectrolytes from the permeate 
solution, as was examined in this study to quantify purification kinetics, could lead to 
recycling of excess polymer to further reduce costs. Overall, our system allows for faster 
synthesis of LbL nanoparticles, with a higher yield as compared to previously described 
methods.
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2.2.2. LbL Modification of Solid Carboxy-Modified Latex and Drug-Loadable Nanoparticle 
Substrates
To confirm that our method retains the desirable versatility of the LbL technique, the 
hydrodynamic size, uniformity, and surface charge were monitored throughout the 
preparation of several different LbL formulations. Initial work focused on solid polymer 
core formulations, such as the 100CML-[PLL/DXS]5 prepared during yield studies (Figure 
2a–c). Another latex core formulation was prepared by depositing alternating layers of 15 
kDa polyethylenimine (PEI) and unfractionated heparin sulfate (HS) onto a 100 nm CML 
substrate (100CML-[PEI/HS]3, see Figure S1). Finally, to demonstrate the capacity to 
prepare smaller sized products, a formulation using 40 nm CML coated with PLL and DXS 
was prepared, reaching a final hydrodynamic size of 58 ± 3 nm, a low polydispersity index 
of 0.12 ± 0.01, and a surface charge of −71.6 ± 0.9 mV (40CML-[PLL/DXS]3, Figure S2).
To demonstrate the fabrication of clinically relevant LbL nanoparticles, focus was shifted to 
the LbL modification of two drug-loadable nanoscale templates, mesoporous silica and 
liposomal vesicles. We successfully prepared LbL nanoparticles from 30 nm mesoporous 
silica coated with poly(L-arginine) (PLA) and poly(L-glutamic acid) (PG) (MSN-[PLA/
PG]3, Figure S3). The final LbL silica particles possessed a hydrodynamic size of 41 ± 4 
nm, a polydispersity index of 0.22 ± 0.02, and a surface charge of −58 ± 2 mV. Subsequent 
efforts focused on the LbL modification of colloidal liposomal cores, where PLL, DXS, and 
HS-containing multilayers were formed on the negatively charged surfaces of doxorubicin-
loaded liposomes (Lipo-[PLL/DXS]4-PLL/HS, Figure 2d–f). An additional LbL liposome 
formulation was prepared using PLA and DXS and later used for freeze-dried storage 
experiments (Lipo-[PLA/DXS]2, Figure S4). Notably, the TFF-assisted method did not need 
to be altered with any of these formulations, with the exception of changing the MWCO of 
the filter membrane when working with smaller or more flexible formulations. For particles 
100 nm or larger in diameter, 500 kDa MWCO membranes were suitable. For smaller 
formulations, or liposomal formulations, 100 kDa MWCO membranes were more 
appropriate. In general, the optimal MWCO was determined by assessing changes in filter 
flux, where if the MWCO was large enough to permit nanoparticle penetration, then a decay 
of flux was observed. If flux decay was observed, the MWCO was decreased until stable 
flux rates were achieved. When changing MWCO of the membrane, the feed flow rate of the 
peristaltic pump was adjusted to keep the transmembrane pressure between 3–5 PSI and the 
shear rate below 6,000 s−1.
Hydrodynamic diameter was tracked using dynamic light scattering (DLS) after each 
purification, and revealed the steady growth from 86 ± 3 nm to a final size of 110 ± 1 nm 
(Figure 2a) for the case of 100CML-[PLL/DXS]5. The Lipo-[PLL/DXS]4-PLL/HS 
formulation exhibited thinner film formation, but nonetheless grew steadily from 58 ± 2 nm 
to 63 ± 2 nm (Figure 2d). The difference between film thicknesses on these two cores was 
anticipated, given previous experience with these substrates.[9b][22][23] In addition to size 
measurements, successful layering was confirmed by tracking the complete charge reversal 
of LbL particles throughout the synthesis. Both 100CML-[PLL/DXS]5 and Lipo-[PLL/
DXS]4-PLL/HS alternated between zeta potentials of roughly +60 mV and −60 mV during 
alternate deposition steps, in accordance to the deposited polyelectrolyte’s charge (Figure 
Correa et al. Page 7
Adv Funct Mater. Author manuscript; available in PMC 2017 February 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2c,f). Nanoparticle uniformity was well preserved throughout the synthesis, as indicated by 
the low polydispersity index (PDI) measured by DLS – 0.06 ± 0.01 for 100CML-[PLL/
DXS]5 and 0.16 ± 0.02 for Lipo-[PLL/DXS]4-PLL/HS (Figure 2b,c). The other LbL 
formulations discussed exhibited similar characteristics, and that data can be seen in the 
online supplemental documentation. Further, population based, documentation on the ten-
layer formulation’s size and charge can also be seen in Figure S5.
To further validate the successful LbL assembly of the two principle formulations, cryogenic 
transmission electron microscopy (Cryo-TEM) was used to evaluate changes in particle 
morphology after LbL modification (Figure 3). Comparison of the electron micrographs 
showed the presence of thin films on the LbL nanoparticles that are not visible on the 
unmodified substrates. These images were further analyzed using ImageJ to quantify size 
changes from the unmodified and layered formulations. The data reveal statistically 
significant (P<0.0001) increases in nanoparticle diameter (for 100CML-[PLL/DXS]5) and 
membrane thickness (for Lipo-[PLL/DXS]4-PLL/HS ) relative to the unmodified substrate 
(Figure 4a–b). Furthermore, comparison of LbL film thickness calculated from either Cryo-
TEM or DLS produced statistically consistent estimates for particles formed on CML (13.3 
± 0.6 nm by Cryo-TEM and 12 ± 1 nm by DLS) and liposomal (2.65 ± 0.09 nm by Cryo-
TEM and 2 ± 1 nm by DLS) substrates (Figure 4c).
These results indicate the highly efficient and scalable fabrication of LbL nanoparticles 
smaller than 150 nm using TFF. Another major finding of this study was that the TFF-
assisted method could be generalized to a diverse number of nanoscale formulations 
including solid latex, mesoporous silica, and liposomal cores. The breadth of 
polyelectrolytes used to construct LbL nanoparticles shows that TFF-assisted LbL assembly 
is compatible with many different material systems. Careful tracking of the nanoparticle 
size, surface charge, and uniformity during synthesis indicated that this method provided a 
great deal of control over these important nanomaterial characteristics. The results from 
Cryo-TEM validated the presence of intact and uniform films on LbL-modified latex 
nanoparticles and liposomes. Furthermore, the agreement between film thicknesses 
calculated from Cryo-TEM or DLS measurements further support the presence of a thin, but 
measurable, film on the nanoparticle surface. These small changes in size are representative 
of the highly controllable growth of the polyelectrolyte multilayer afforded by the LbL 
technique. The generalizable nature and excellent quality control of this method has 
important implications for the future of basic research into LbL nanomedicines, as TFF is a 
highly accessible technology that could be employed by most laboratories.
2.3. Generation of an LbL Small Library
The generation of a small library of LbL nanoparticles demonstrated the potential of TFF-
assisted LbL assembly to increase experimental throughput, allowing researchers to better 
evaluate the contribution of different variables in their nanoparticle formulations. Since one 
of the greatest strengths of the LbL platform is its ability to generate diverse material 
systems, there is a large parameter space to be explored. It has been well documented that 
nanoparticle surface chemistry plays an important role in particle-cell interactions.[24] The 
work by Murphy and colleagues has highlighted several biological effects of LbL 
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nanoparticles that depend on surface chemistry, demonstrating the importance of broadly 
studying different terminal coatings.[9a, 25] To this end, ten unique LbL nanoparticle 
formulations were generated from 100 nm CML cores. Each particle was coated with PLA 
and then terminated with one of ten polyanions described in Table 1. These terminal coats 
include a variety of polysaccharides, linear polypeptides, and synthetic or modified 
polymers. In particular, the hyaluronic acid and heparin-folate conjugate coated formulations 
possess known targeting properties.[26] Of note, the inclusion of hyaluronic acid into LbL 
particles can be challenging due to the polymer’s propensity to form secondary and tertiary 
structures that can drive aggregation.[27] However, hyaluronic acid is a highly desirable 
material that benefits biomedical applications with its unique biological behaviors such as 
mucoadhesion, receptor targeting, and antifouling.[4a, 11, 28] Use of the TFF-assisted method 
greatly increased the throughput of nanoparticles functionalized with hyaluronic acid (ca. 
10-fold per particle). Each particle prepared for the library exhibited excellent size, 
uniformity, and surface charge, consistent with the descriptions of the more highly layered 
formulations.
Importantly, this work describes the manufacture of several novel LbL formulations that 
incorporated sulfated beta-cyclodextrin polymer, the algae-derived polysaccharide fucoidan, 
and a heparin sulfate-folate conjugate. The fabrication of stable LbL particles composed of a 
cyclodextrin polymer opens the door to generating LbL films with drug-loaded 
polyelectrolytes for the inclusion of hydrophobic small molecules. LbL nanoparticles coated 
with fucoidan present opportunities to investigate emergent reports of this molecule’s 
involvement in cellular differentiation and immune modulation.[29] The inclusion of a 
heparin-folate conjugate also raises opportunities to leverage both molecules’ biological 
interactions towards an effective targeted therapy. Furthermore, given the success of this 
technique with a variety of material systems, it is likely that this approach could be adapted 
to prepare LbL formulations that utilize alternative attractive forces such as hydrogen 
bonding and hydrophobic interactions.
2.4. Evaluation of LbL Nanoparticle Toxicity
To address the concern that TFF-made LbL nanoparticles may have unintended cytotoxic 
effects due to the carryover of excess polycation, a viability assay was performed on SKOV3 
cells with three LbL formulations. Poly(L-aspartic acid), hyaluronic acid, and heparin sulfate 
terminated nanoparticles were prepared by either the TFF-method or the conventional 
centrifugal method and incubated with SKOV3 cells over the course of 72 hours. Cell 
viability was measured at 24, 48, and 72 hours and compared to the viability of untreated 
cells and cells exposed to the bare latex core (Figure 5 and Figure S6). None of the 
nanoparticle formulations exhibited statistically significant changes in viability compared to 
untreated controls, indicating that TFF-made LbL nanoparticles show low toxicity in vitro.
These results provide evidence that LbL nanoparticles prepared using the TFF method are 
cell-compatible by performing a head-to-head comparison of toxicities between several 
formulations. The results further prove that TFF purification provides highly pure LbL 
nanoparticles free of cytotoxic contaminants such as free polyelectrolytes.
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2.5. LbL Nanoparticle Refrigerated Shelf-Life
The capability to increase the scale, yield and throughput of LbL preparations is an 
important step towards realizing clinical translation. Another important factor for translation, 
which to our knowledge has not been addressed previously for LbL nanoparticles, is their 
shelf life. We evaluated whether appreciable destabilization would occur with nanoparticles 
from our small library during a three-month storage period in pure water at 4°C. We found 
that LbL nanoparticles broadly retained their number-average and z-average sizes, as well as 
their low PDI and high zeta potentials (Figure 6). Relative to the freshly prepared 
nanoparticles, nine out of ten formulations exhibited statistically consistent hydrodynamic 
sizes. Using the more aggregate-sensitive size determinant, z-average size, seven out of ten 
formulations retain their original size. Interestingly, the PDI of all formulations remained 
statistically consistent during storage, which may indicate that size changes are due more to 
swelling of the film than to aggregation events. Furthermore, the zeta potential of the LbL 
nanoparticles remained very high during storage, although some statistically significant 
changes were noted. Two formulations (HA and DXS-terminated) exhibited minor but 
significant (P<0.05) loss of charge. On the other hand, sulfated beta-cyclodextrin-terminated 
particles exhibited a modest (14.9 mV) and significant (P<0.001) increase in magnitude of 
surface charge during storage. Overall, these data suggest that LbL formulations are stable 
on the order of at least 3 months when stored under refrigerated, aqueous conditions. 
Stability is important because it indicates that these formulations could be kept at-the-ready 
in clinical settings, and furthermore, could facilitate use in clinical settings by minimizing 
the need for constant reconstitution prior to administration.
2.6. Freeze-dried, Room Temperature Storage of Drug-loaded LbL Liposomes
Refrigerated storage can pose its own problems for clinical translation in terms of 
transportation and accessibility. Moreover, storing LbL nanoparticles in an aqueous state can 
allow for the slow release of encapsulated small molecule drugs. With this in mind, 
lyophilization and room temperature storage of freeze-dried powders is ultimately a far more 
convenient and manageable option for clinical and industrial scale operations.[30] To 
determine if LbL nanoparticles can survive such storage conditions, the doxorubicin-loaded 
Lipo-[PLA/DXS]2 formulation was used as a model system for cryogenic storage. LbL 
liposomes were combined with several different cryoprotectants (5% glucose, 10% sucrose, 
11% trehalose), and with or without a poly(vinyl alcohol) preservative (PVP). LbL-modified 
and bare liposomes were flash-frozen in liquid nitrogen and lyophilized to produce a fluffy, 
cotton-like powder (Figure 7a). The powder was kept at room temperature for a week prior 
to being reconstituted in pure water.[31] The reconstituted particles were dialyzed overnight 
and then analyzed to determine if particle integrity or drug encapsulation had been 
compromised.
The results indicated that LbL liposomes protected their drug payload better than bare 
liposomes under these storage conditions (Figure 7c). In five out of seven conditions, 
including the cryopreservative-free control, statistically significant (P<0.05 or P<0.01) 
improvements in retention relative to bare liposomes were observed. Notably, preservation 
by 5% glucose or 11% trehalose led to virtually no drug loss in LbL liposomes (97 ± 3% and 
97 ± 2% encapsulation, respectively). The rest of the formulations retained at least 89% of 
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the drug payload, whereas the liposomes only retained 79–89% of their encapsulated drug 
after reconstitution.
Generally, we observed that inclusion of PVP was detrimental to overall stability of these 
nanoparticles. These results are consistent with previous work, which demonstrated that 
poly(vinyl acid)-based preservatives fail to adequately stabilize liposomes unless 
modified.[32] In contrast, it has been seen that PVP is sufficient for protection of polymeric 
nanoparticles, such as those composed of poly(dl-lactide-co-glycolide), poly (D,L-lactic 
acid), and poly(lactic acid-co-ethylene oxide).[33] Therefore, the presence of a polymeric 
film on the LbL-coated liposomes may help to explain their better stability relative to bare 
liposomes when lyophilized in the presence of PVP.
Cryoprotectants were found to be essential for LbL nanoparticle survival under long-term 
storage conditions. Without cryoprotectants, LbL particles undergo irreversible aggregation 
into micron-sized particles. With protectants, there is no statistically significant impact on 
LbL nanoparticle size after freeze-dried storage (Figure 7d, Figure S7). On the other hand, 
the use of cryoprotectants led to statistically significant (P<0.001) increases in the z-average 
diameter of bare liposomes (Figure S7). Inclusion of PVP partially rescued liposomes 
protected with either glucose or sucrose, but the resulting z-average size was still 
significantly larger than the original formulation. Bare liposomes also undergo statistically 
significant (P=0.001) increases in PDI after reconstitution, in contrast to LbL liposomes, 
which retain low PDIs that are statistically consistent with their original PDI (Figure 7e).
Zeta potential measurements of the reconstituted particles indicated that the choice of 
cryoprotectant was important in preserving the original surface charge on LbL nanoparticles 
(Figure 7f). Either 10% sucrose or 11% trehalose managed to prevent any decrease in zeta 
potential for LbL particles. These results are consistent with prior work, which demonstrated 
that disaccharides are more suitable cryoprotectants for lipid-based nanoparticles than 
monosaccharides.[34] Overall this choice of cryoprotectant is an important characteristic to 
optimize, as loss of surface charge may compromise the reconstituted particle’s shelf life or 
further in vivo stability.
Overall, these results strongly indicate that LbL liposomes can be stably stored under freeze-
dried, room-temperature conditions. This finding has major implications for the clinical and 
industrial translatability of this technology, as it would facilitate the stockpiling, shipping 
and distribution of future nanomedicines. Our work compared the efficacy of several 
cryoprotectants head-to-head, and revealed that 11% trehalose was the most consistent 
protectant and maintained the size, uniformity, and charge of our LbL liposomes. 
Furthermore, preservation by trehalose facilitated high drug payload retention, with a 97 
± 2% encapsulation of doxorubicin. Notably, LbL liposomes exhibited superior drug cargo 
retention compared to bare doxorubicin-containing liposomes, and could represent a safe 
and straightforward means towards the improvement of already clinically approved 
nanotherapies that may suffer from suboptimal drug-retention under storage.
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3. Conclusion
LbL nanoparticles represent a desirable class of materials that are modular, hierarchical, and 
multifunctional. These characteristics are critical for the advancement of potent next-
generation nanomedicines. Until now, these materials were difficult to prepare, despite their 
straightforward assembly behavior. So far, intermediate purification steps between layer 
depositions presented the greatest barrier for both lab scale research and clinical translation. 
Here we described a solution to this bottleneck by using tangential flow filtration to handle 
the cumbersome and time-consuming washing steps. This approach did not restrict the 
hallmark versatility of LbL assembly, allowing us to prepare nanoparticles ranging from 40 
to 150 nm from solid polymer, mesoporous silica, and liposomal substrates. Furthermore, 
this technique was compatible with several distinct LbL formulations composed of over a 
dozen biologically relevant polyelectrolytes. This versatility was accompanied by rapid 
purification/processing times, excellent product yields, and control over important 
nanoparticle characteristics (e.g., size, uniformity, and surface charge). This approach has 
the potential to become fully automated, which would benefit the colloidal LbL community 
in a similar way that robotic dipping machines have enhanced research into the LbL 
modification of macroscopic substrates. In particular, future work that focuses on 
incorporating programmable, robotic operation of TFF devices would provide hands-off 
synthesis of LbL nanomaterials.
This report also highlights that LbL materials can be stored in aqueous, refrigerated 
conditions on the order of months. Additionally, we demonstrate that LbL liposomes loaded 
with small molecule drugs, namely doxorubicin, can be stored under freeze-dried, room 
temperature conditions without compromising drug encapsulation or nanoparticle 
characteristics. Overall, this work provides a new path towards ramping up basic research 
into this important class of drug-delivery vehicles, as well as a means to scale-up existing 
and future technologies to the clinic.
4. Experimental Section
Colloidal Substrate And Polyelectrolyte Preparation
The polyelectrolytes poly(L-lysine) HBr (PLL, 4–15 kDa; Sigma Aldrich), dextran sulfate 
sodium salt (DXS, 6.5–10 kDa; Sigma Aldrich), poly(acrylic acid) (PAA, 15 kDa; Sigma 
Aldrich), poly(L-arginine) (PLA, 9.6 kDa; Alamanda Polymers), poly(L-glutamic acid) (PG, 
15 kDa; Alamanda Polymers), poly(L-aspartic acid) (PD, 14 kDa; Alamanda Polymers), 
poly(L-glutamic acid)-b-polyethylene glycol (PG-b-PEG, 30 kDa PG, 5 kDa PEG; 
Alamanda Polymers), linear polyethylenimine (PEI, 25 kDa, Polysciences), hyaluronic acid 
(HA, 40 kDa; LifeCore Biomedical), sulfated beta-cyclodextrin polymer (18kDa; 
Cyclodextrin Technologies), and fucoidan (57 kDa; Santa Cruz Biotechnology) were used 
without modifications. Heparin sodium salt (HS, unfractionated; Celsus Labs) was used both 
unmodified and as a conjugate with folic acid (Sigma Aldrich) as described previously.[35] 
For additional detail on the synthesis see supplemental section online.
Correa et al. Page 12
Adv Funct Mater. Author manuscript; available in PMC 2017 February 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The fluorescent, carboxylate-modified latex nanoparticles (100 nm, blue fluorescent 
(350/440) and 40 nm yellow-green fluorescent (505/515); Life Technologies) were used 
without modification.
Mesoporous silica nanoparticles were prepared according to the protocol for 40 nm particles 
described by Zhang and coworkers.[36] The procedure was as follows: (i) 1.52 g of 
hexadecyltrimethylammonium bromide (CTAB, Sigma Aldrich), 0.35 g triethanolamine 
(0.311 mL, Sigma Aldrich), and 100 mL Millipore water were mixed and heated at 80ºC for 
1 hour, until dissolved. (ii) 14.6 g of tetraethyl orthosilicate (Sigma Aldrich) was added 
quickly to the solution, which was left stirring for another 2 hours. (iii) Particles were 
isolated by high-speed centrifugation (30,000 × g for 1 hour) and washed once with water 
and then once more with methanol. Particles were resuspended in methanol for CTAB 
extraction (iv) Template removal was accomplished by first adding 1 mL of 12 M HCl 
followed by refluxing the solution at 80 ºC for 14 hours. (v) The silica particles were 
recovered by centrifugation and washed twice with methanol prior to being dried under 
vacuum. For LbL preparations, dried silica was reconstituted in Millipore water. The size of 
these particles was measured to be 30 ± 10 nm by dynamic light scattering. For the porosity 
of these nanoparticles, the reader is referred to the original paper describing this protocol.[36]
Doxorubicin-loaded liposomes were prepared as follows: (i) 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC; Avanti Polar Lipids), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
(1'-rac-glycerol) sodium salt (POPG; Avanti Polar Lipids), and cholesterol (Sigma Aldrich) 
prepared at a 56:5:39 weight ratio were dissolved in a cosolvent of cholesterol and methanol 
(2:1 volume ratio). (ii) The solution was evaporated using a rotary evaporator at 40°C at 150 
mbar to make a thin lipid film. (iii) The film was hydrated in 300 mM citric acid buffer (pH 
4) under sonication at 65°C until uniform liposomes are generated. (iv) 300 mM sodium 
carbonate buffer was added into the liposome solution to adjust the pH of the solution to 6.5, 
which generated a pH gradient between the buffer solution outside liposomes and the 
internal environment of liposomes. (v) Doxorubicin HCl salt (Dox; LC Laboratories) was 
dissolved at 3 mg mL−1 in sodium chloride solution (154 mM, 0.9 wt/vol %), and the Dox 
solution was added into the liposome solution under sonication at 65°C for 5 min. Dox-
loaded liposomes were purified using the TFF system (500 kDa MWCO filter module; 
Spectrum Labs) as described below.
Tangential Flow Filtration Assisted LbL Fabrication
Colloidal substrates (CS) and polyelectrolytes (PE) were dissolved in equal volumes of 
purified water at a 1:5 mass ratio of CS to PE. Prior to the first layer deposition, the CS 
solution was sonicated for 5 minutes and the PE solution for 15 minutes to disrupt any pre-
existing aggregates. The CS solution was added to the PE solution under sonication to 
generate the PE film. Once mixed, the CS-PE mixture was sonicated for 5 more seconds and 
incubated on an orbital shaker for 15 minutes. The CS-PE mixture was then transferred to a 
50 mL conical flask (Corning) and connected to a tangential flow filtration (TFF) device 
(KrosFlo Research IIi; Spectrum Labs). All connections were made using MasterFlex size 
14 Pharma-Pure tubing, with the exception of the tubing that runs through the peristaltic 
pump, which is size 16. The TFF was connected to a suitable filtration membrane composed 
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of modified polyethersulfone, either a 100 kDa MWCO or a 500 kDa MWCO membrane 
(Spectrum Labs, MidiKros Class) depending on the size of the CS being used. Refer to the 
supplemental information for a video showing the experimental set up.
The filter membranes were used exclusively with one charge type to prevent product loss 
and membrane fouling. The membrane used to process positively charged nanoparticles is 
pre-processed by recirculating salt-free, cationic PE solution for 10 minutes to mask anionic 
sites. The negative-particle membrane is used without further modification.
The CS-PS mixture was pumped with a constant feed rate (190 mL min−1 for 500 kDa 
membrane and 170 mL min−1 for 100 kDa membranes) through the appropriate TFF 
membrane using a peristaltic pump. Feed rate was chosen to maintain a transmembrane 
pressure between 3–5 PSI and a shear rate below 6,000 s−1. These values were calculated 
using the provided software and sensors within the TFF device.
To maintain a constant sample volume during purification, a 2 L buffer reservoir filled with 
Millipore water was connected to the sample container. The CS-PE mixture was washed 
until 5 complete volumes were eluted (for a 40 mL sample that would be 200 mL of 
permeate) when using a 500 kDa membrane. With the 100 kDa membrane, 7 complete 
volumes were eluted. Permeate solution was collected in sequential 20 mL aliquots to 
determine purification kinetics as described below.
After adequate purification, the nanoparticle sample was disconnected from the buffer 
reservoir in order to concentrate the pure product down to 20 mL in anticipation for the next 
layer deposition. At this stage, samples were taken for characterization of the nanoparticles 
as described below.
After removing the pure CS sample from the TFF device, another layer was deposited as 
before, with an oppositely charged PE solution. During this incubation, filter membranes 
were briefly rinsed with water and switched to the appropriate charge-specific membrane for 
the next purification. This process was repeated until reaching the desired number of layers.
Note that the mass ratio of 1:5 for substrate to polyelectrolyte generally yielded stable layer 
depositions, but for certain polyelectrolytes the ratio was shifted until a zeta potential 
measurement with a magnitude of at least 40 mV was observed in the unpurified mixture. 
For example, our CML cores were used at a 1:5 mass ratio with PLL, whereas we used a 1:3 
mass ratio with DXS, which equates to 10 mg of PLL and 6 mg of DXS being used per layer 
deposition during the modification of 2 mg of CML substrates.
Characterizing Purification Kinetics and Yield
Permeate samples were taken from purifications involving PLL and DXS. To quantify the 
amount of PLL extracted using the TFF, we directly analyzed the PLL permeate samples as 
well as PLL standards using the bicinchoninic assay (BCA; Pierce). Absorbance 
measurements were taken with a TECAN Infinite M200 Pro plate reader and used to 
calculate the mass of PLL removed from the system.
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The concentration of DXS in the permeate was determined by gel permeation 
chromatography (GPC). DXS permeate samples and standards were lyophilized and 
redissolved in the appropriate GPC eluent. The measurements of DXS was performed on an 
Viscotek GPCmax system (Malvern) equipped with Agilent PL aquagel-OH columns (PL 
aquagel-OH Guard 8 μm (50 mm × 7.5 mm), and PL aquagel-OH MIXED-M 8 μm (300 mm 
× 7.5 mm, exclusion limit > 6×105 g mol−1)) thermostated to 35°C and a refractive index 
detector maintained at 35°C. 100 mM NaNO3 and 10 mM NaH2PO4 in aqueous solution at 
pH 7.4 containing 4:1 (v/v) MeOH was used as mobile phase with a flow rate of 1.0 mL 
min−1. The refractive index area (mVmL) of each sample (injection volume constant at 50 
μL) was measured and calibrated against a DXS standard curve.
To determine nanoparticle yields, purified product was weighed in tared conical flasks to 
determine recovered sample volume. Then, 10 μL samples of the product were taken and 
diluted to 100 μL in pure water and analyzed using the Infinite M200 plate reader. Sample 
fluorescence measurements (350 nm excitation, 440 nm emission) were compared to 
standards of known CML concentration in order to calculate the product yield.
For LbL nanoparticles prepared by centrifugation, instead of processing with the TFF the 
nanoparticle solution was centrifuged at 15,000 rcf for 15 minutes. Supernatant was 
removed and spun again until no nanoparticle pellet was formed, about 6 spins total per 
layer. Recovered pellets were gently resuspended in pure water, to avoid dislodging any 
insoluble aggregates from the tube wall. HA terminated nanoparticles was spun at 10,000 rcf 
for 5 minutes to minimize product loss.
Lbl Liposome Lyophilization And Storage
Samples were prepared with cryoprotectant (5% glucose, 10% sucrose or 11% trehalose; 
Sigma Aldrich), cryoprotectant plus poly(vinyl alcohol) preservative (PVP, Mowiol 4–88; 
Sigma Aldrich), or without any stabilizer. Samples were flash frozen in liquid nitrogen for 
15 minutes and lyophilized for 48 hours. The freeze-dried powders were backfilled with N2 
and stored at room temperature on the bench top for a week prior to reconstitution in pure 
water (reverse osmosis, MilliQ) followed by an overnight equilibrium dialysis (8 kDa 
MWCO, 4C).
Nanoparticle Characterization
Hydrodynamic size and polydispersity index were measured using dynamic light scattering 
(Malvern ZS90 particle analyzer, λ = 633 nm, material/dispersant RI 1.590/1.330). Zeta 
potential measurements were made using laser Doppler electrophoresis with the Malvern 
ZS90 as well. All measurements were conducted in water (reverse osmosis, MilliQ). Cryo-
TEM was performed with a JEOL 2100 FEG instrument, and quantitative image analysis 
was performed using ImageJ software. For Cryo-TEM, 3 uL of the sample solution was 
dropped onto a lacey copper grid coated with a continuous carbon film. The sample was 
blotted to remove excess liquid by Gatan Cryo Plunge III. The grid was mounted on a Gatan 
626 cryo-holder, and then the specimen and holder tip were cooled using liquid nitrogen. 
Imaging was performed using the minimum dose method to prevent damage to the sample 
by the electron beam. The microscope was operated at 200 kV with a magnification setting 
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of 10,000–30,000 for assessing particle size and distribution. All images were then recorded 
on a Gatan 2kx2k UltraScan CCD camera. Conventional TEM was conducted using either a 
FEI Tecnai Multipurpose TEM (120 kV) or JEOL 2011 High Contrast Digital TEM (120 
kV). Specimens for conventional TEM were prepared by drop-casting nanoparticle solutions 
onto mesh copper grid coated with a continuous carbon film.
Drug encapsulation was determined for Dox-loaded nanoparticles by measuring Dox 
fluorescence (500 nm excitation, 600 nm emission) from particle and diafiltrate solutions 
(50% DMSO) following an overnight equilibrium dialysis (8 kDa MWCO, 4C) against 
lyophilization solutions. Fluorescence measurements were made using the Infinite M200 
plate reader.
Cytotoxicity Characterization
SKOV3 (ATTC) ovarian cancer cells were maintained in regular Dulbecco’s modified Eagle 
medium (DMEM, Corning) supplemented with 10% fetal bovine serum (Seradigm) and 1% 
penicillin-streptomycin (Corning). Cells were seeded in tissue-culture grade 96-well plates 
(Greiner) at a density of 5,000 cells per well the night before treatment with LbL 
nanoparticles. The next day, the cells were incubated in media containing a 20 pM 
concentration of LbL nanoparticles. At the reported time points, the cellular viability was 
determined using the Cell-Titer Glo luminescence assay (Promega).
Data Processing And Statistical Analysis
Purification kinetics data were fit to a one-phase exponential decay model with PRISM 
software. The model constrained y0 (set to 0), plateau (set to known amount introduced into 
the system), and K (must be greater than 0). PRISM was also used to fit a basic linear model 
to yield data.
One-way ANOVA with the Bonferroni post-test was used to determine statistically 
significant differences in most cases (results from this test are annotated in gray on all plots). 
To assess statistically significant changes between original nanoparticles and the various 
cryogenic storage conditions, one-way ANOVA with the Dunnet post-test was performed. 
Determinations from this particular test are denoted in blue (for LbL particles) and red (for 
bare liposomes) in Figure 7. Unless noted otherwise, alpha was set to 0.01 (99% 
confidence). All tests were conducted in PRISM software.
Size measurements taken from ImageJ were imported and analyzed in R studio. The data 
were visualized as probability density histograms, and overlaid with their kernel density 
distribution estimate using the ggplot2 package. Size and charge distribution data exported 
from the Malvern Zetasizer software were processed in Microsoft excel to convert the raw 
data into a frequency table for import into R studio. The distributions were then plotted 
using the violinplot functionality of the ggplot2 package to produce the figures seen in the 
supplemental documentation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Tangential flow filtration (TFF) facilitates the rapid and controlled fabrication of layer-by-
layer nanoparticles. (a) TFF purification schematic depicting continuous diafiltration 
through a porous membrane. A peristaltic pump drives nanoparticle samples through a 
circuit containing a filter membrane. Polyelectrolytes, driven by a mild pressure gradient, 
exit the circuit through the pores in the filter membrane and into a waste reservoir. Removal 
of solution generates a vacuum within the system, which draws replacement buffer from an 
attached reservoir to hold sample volume constant. To prevent nonspecific adsorption onto 
the filter membrane, purification of cationic and anionic nanoparticles was separated to 
different purification loops, each with its own filtration membrane. The left panel denotes 
the cationic purification loop, and the right panel denotes the anionic purification loop. (b) 
Purification of excess poly-L-lysine (PLL) or dextran sulfate (DXS) following LbL 
deposition can be completed in minutes using TFF. The concentration of PLL extracted 
using TFF was determined using a BCA assay on samples taken sequentially from the waste 
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stream. DXS concentrations were determined by analyzing permeate samples by gel 
permeation chromatography. Data were fitted using a one-phase exponential decay model. 
(c) High yields (68 ± 5% after 10 layers) are reproducibly obtained using TFF-assisted LbL 
fabrication. Nanoparticle concentration was quantified using a fluorescence plate reader 
following each purification step during the fabrication of 100 nm, carboxy-modified latex 
particles coated with five bilayers of PLL and DXS (CML-[PLL/DXS]5). Error bars 
represent standard deviation of three independent syntheses.
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Figure 2. 
Diverse layer-by-layer (LbL) nanoparticles are prepared in a controlled manner using the 
tangential flow filtration (TFF)-assisted method. (a–c) Solid-core LbL particles were 
prepared by coating 100 nm, carboxy-modified latex particles with five bilayers of poly(L-
lysine) and dextran sulfate (100CML-[PLL/DXS]5). (d–f) Liposomal-core LbL particles 
were prepared by coating negatively charged, doxorubicin-containing liposomes with four 
bilayers of PLL and DXS followed by a bilayer of PLL and heparin sulfate (Lipo-[PLL/
DXS]4-PLL-HS). (a, d) These particles exhibited controlled size increase during layer 
deposition. (b, e) Nanoparticle uniformity was maintained throughout the layering process 
as indicated by the low polydispersity index (PDI). (c, f) Complete charge reversal was 
observed after each layer deposition indicating successful LbL modification. Size and 
polydispersity data were acquired by dynamic light scattering, and zeta potential data was 
measured using laser Doppler electrophoresis. Error bars represent standard deviation of 
three technical replicates. For population-based data see Supplemental Figure S5.
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Figure 3. 
Cryogenic TEM images of core particles before and after layering confirm the presence of a 
thin film. Cryogenic TEM of (a) uncoated, carboxy-modified latex particles; (b) purified, 
LbL-coated carboxy-modified latex (CML-[PLL/DXS]5); (c) uncoated, doxorubicin-loaded 
liposome; (d) purified, LbL-coated, doxorubicin-loaded liposome (Lipo-[PLL/DXS]4-PLL-
HS).
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Figure 4. 
The quantification of Cryo-TEM images confirm statistically significant increases in size 
consistent with LbL modification. (a) Comparison of the diameters of bare, carboxy-
modified latex (CML) particles and LbL-modified CMLs indicate a statistically significant 
(P<0.0001) shift in the size distribution. Dashed line denotes the mean size. N = 103 for bare 
and 153 for LbL CML. (b) Similarly, comparison of the liposome membrane thickness 
reveals statistically significant (P<0.0001) increase in thickness after LbL modification. 
Dashed lines denote the mean thickness. N = 113 for bare and 298 for LbL liposomes. (c) 
Calculation of LbL film thickness from either Cryo-TEM data or dynamic light scattering 
data give statistically consistent results for both CML (13.3 ± 0.6 nm by Cryo-TEM and 12 
± 1 nm by DLS) and liposomal (2.65 ± 0.09 nm by Cryo-TEM and 2 ± 1 nm by DLS) 
substrates. Error bars represent SEM. These data highlight important changes in LbL film 
thickness due to substrate selection. Individual particle measurements were plotted as a 
histogram and the kernel density function was estimated using R Statistical Software. All 
statistical tests were performed using one-way ANOVA (alpha = 0.01), with the Bonferroni 
post-test, on PRISM graphing software.
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Figure 5. 
LbL nanoparticles prepared using the TFF-assisted method do not exhibit nonspecific 
cytotoxic effects in vitro. SKOV3 cells were incubated with poly(L-aspartic acid), herparin 
sulfate, and hyaluronic acid terminated LbL nanoparticles that were prepared by either the 
TFF method (solid, blue bars) or the conventional centrifugal method (striped bars). After 72 
hours, the cellular viability was determined using the Cell-Titer Glo luminescence assay. 
The results were normalized relative to untreated controls, and subsequent analysis by one-
way ANOVA failed to find any statistically significant changes in cellular viability for any 
formulation, regardless of preparation method.
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Figure 6. 
LbL nanoparticles have long refrigerated shelf lives as indicated by the preservation of their 
size, uniformity and charge characteristics. Ten different LbL particles consisting of a 
carboxy-modified latex core and a bilayer of poly(L-arginine) and a unique polyanion were 
stored for three months at 4 degrees Celsius. (a) We compared the hydrodynamic number 
average size for the particles after storage and compared them to the particle’s original size. 
With the exception of the Fucoidan-coated particle, all others maintained statistically 
consistent sizes during storage. (b) These particles likewise exhibited statistically consistent 
polydispersity index, suggesting that particle uniformity is maintained during storage. (c) 
The z-average size measurement, which is more sensitive to aggregates, demonstrated that 7 
out 10 formulations exhibited statistically consistent sizes during storage. (d) Generally, the 
zeta potential of the nanoparticles was conserved during storage with a few exceptions. 
Sulfated beta cyclodextrin-coated particles exhibited a significant charge increase during 
storage. On the other hand, hyaluronic acid and dextran sulfate-coated particles exhibited a 
small, but statistically significant decrease in zeta potential. Overall these data indicate that 
LbL particles would be amenable to months-long refrigerated storage without concern of 
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loss of colloidal stability. One-way ANOVA with the Bonferroni post-test (alpha = 0.01) was 
used to determine statistical significance between the indicated samples.
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Figure 7. 
Liposomal-core layer-by-layer nanoparticles can be lyophilized and reconstituted for long-
term storage. Doxorubicin-loaded liposomes were coated with two bilayers of poly(L-
arginine) and dextran sulfate (Lipo-[PLA/DXS]2), using the TFF-method. (a) Lipo-[PLA/
DXS]2 particles were lyophilized with different cryopreservatives. (b) TEM of particles 
before lyophilization (left panel) and after being reconstituted from freeze-dried powder 
(right panel). (c) LbL modified liposomes retained more drug than bare liposomes regardless 
of choice of cryoprotectant, though several protectants facilitate nearly 100% drug retention 
during storage and reconstitution. (d) The presence of cryoprotectants prevents aggregation 
upon LbL liposome reconstitution. (e) Reconstituted LbL liposomes exhibit lower 
polydispersity index than reconstituted bare liposomes, indicating improved uniformity. (f) 
Cryopreservation with 10% sucrose or 11% trehalose prevented decreases in the zeta 
potential of LbL liposomes. Size and polydispersity data were acquired by dynamic light 
scattering, and zeta potential data was measured using laser Doppler electrophoresis. Error 
bars represent standard deviation of three technical replicates.
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Table 1
Ten formulations of LbL nanoparticles with unique terminal polymer layers were fabricated using the TFF 
method. Each particle is a bilayer formed on carboxy-modified polystyrene substrates (CML-[poly(L-
arginine)/polymer X], where polymer X is one of the terminal layers described below). The size, uniformity 
and zeta potential of each nanoparticle formulation was determined by dynamic light scattering and laser 
Doppler electrophoresis. Error represents the standard deviation of three technical replicates.
Terminal Layer Average Hydrodynamic Size [nm] Polydispersity Index Zeta Potential [mV]
Carboxy-modified latex 95 ± 5 0.10 ± 0.03 −63 ± 1
Poly(L-arginine) 105 ± 2 0.03 ± 0.01 66 ± 1
Poly(L-aspartic acid) 101 ± 9 0.08 ± 0.02 −63 ± 1
Poly(L-glutamic acid) 106 ± 3 0.04 ± 0.04 −61 ± 1
Poly(L-glutamic acid)-b-polyethylene glycol 105 ± 9 0.08 ± 0.01 −51 ± 3
Poly(acrylic acid) 99 ± 7 0.05 ± 0.03 −68 ± 2
Hyaluronic acid 153 ± 8 0.05 ± 0.02 −56 ± 2
Dextran sulfate 109 ± 9 0.13 ± 0.04 −75 ± 1
Heparin-folate conjugatea) 120 ± 9 0.07 ± 0.03 −61 ± 2
Sulfated beta cyclodextrin polymer 110 ± 8 0.05 ± 0.06 −50 ± 2
Heparin sulfate 107 ± 4 0.11 ± 0.04 −73 ± 2
Fucoidan 126 ± 4 0.12 ± 0.05 −61 ± 1
a)
Heparin sulfate was conjugated to folic acid using NHS addition chemistry. See supplemental information for more detail.
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